AS PART of the Therapeutic Goods Administration's (TGA's)ongoing post-market review of listed medicines, it is investigating all listed medicines to assess their claims around treatment of macular degeneration.
Sponsors are warned to ensure their product indications are not directly or indirectly referencing macular degeneration, that there is strong evidence to support all indications and that product names are not "potentially misleading" within the context of the goods.
Beause of the severity of macular degeneration and that it can lead to blindness, it is described as a "restricted representation for listed medicines" - see tga.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 16 Jun 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 Jun 17